BridgeMD
Tests treatment safety and results for Erythematotelangiectatic Rosacea
Official title The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea
ClinicalTrials.gov ID: NCT07343635
What this study is testing
What is Doxycycline?
Doxycycline is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for erythematotelangiectatic rosacea.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- The people are male or female, aged 18 to 70 years (inclusive); they voluntarily participate in this study and sign the informed consent form.
- They are diagnosed with erythematous telangiectatic rosacea, meeting the diagnostic criteria in the "Chinese Guidelines for the Diagnosis and...
- At screening and baseline, the IGA score is 2 (mild) or 3 (moderate).
- The people agree not to use any other rosacea treatment drugs (prescription or over-the-counter) during the study period.
- The people are willing to minimize external factors that may trigger rosacea (such as spicy food, alcoholic beverages, prolonged sun exposure, etc.).
You likely can't join if
- Diagnosed as papulopustular, hypertrophic, ocular rosacea or other special types of rosacea
- Other facial skin diseases that were active during the screening period or baseline may interfere with the how well it works/safety assessment of...
- people who have underlying known diseases or medical conditions, or who have undergone major surgeries within the six months prior to screening...
- During the screening period or at baseline, researchers evaluate abnormal laboratory test results with significant clinical significance;
- Those who have received LED light therapy for their faces in the past two weeks;
- Those who have received laser, intense pulsed light (IPL), fractional microneedle radiofrequency treatment, CO2 exfoliating fractional laser...
See the full eligibility criteria
- The people are male or female, aged 18 to 70 years (inclusive); they voluntarily participate in this study and sign the informed consent form.
- They are diagnosed with erythematous telangiectatic rosacea, meeting the diagnostic criteria in the "Chinese Guidelines for the Diagnosis and Treatment of Rosacea (2021)".
- At screening and baseline, the IGA score is 2 (mild) or 3 (moderate).
- The people agree not to use any other rosacea treatment drugs (prescription or over-the-counter) during the study period.
- The people are willing to minimize external factors that may trigger rosacea (such as spicy food, alcoholic beverages, prolonged sun exposure, etc.).
- The people (including their partners) agree that they have no plans to conceive within 3 months after signing the informed consent form until the end of the last treatment and are willing to take effective contraceptive...
- Diagnosed as papulopustular, hypertrophic, ocular rosacea or other special types of rosacea
- Other facial skin diseases that were active during the screening period or baseline may interfere with the how well it works/safety assessment of erythematous vasodilating rosacea, including but not limited to perioral...
- people who have underlying known diseases or medical conditions, or who have undergone major surgeries within the six months prior to screening, where, based on the researcher's judgment, the people are at risk (such as...
- During the screening period or at baseline, researchers evaluate abnormal laboratory test results with significant clinical significance;
- Those who have received LED light therapy for their faces in the past two weeks;
- Those who have received laser, intense pulsed light (IPL), fractional microneedle radiofrequency treatment, CO2 exfoliating fractional laser treatment, electrocoagulation, dermabrasion, chemical peels, or any facial...
- Facial active infections who are currently receiving or require systemic treatment (systemic antibiotics, antifungal, antiviral drugs) - including bacterial pustules, fungal folliculitis, herpeder-like skin lesions and...
- Local/systemic treatment that did not complete an adequate elution period before baseline, including: Glucocorticoids (corticosteroids), calcineurin inhibitors (such as tacrolimus, pimecrolimus), Janus kinase...
- Use drugs that cause acne-like rashes simultaneously (such as azathioprine, haloperidol, halogens, lithium, systemic corticosteroids, phenytoin sodium, phenobarbital, testosterone, anabolic steroids, isoniazid);
- Those who have used astringents/exfoliating products (cleansing or exfoliating products containing salicylic acid or alcohol) within the past 2 days or are planned to use them during the study period;
- The subject has a history of alcohol abuse (drinking more than 14 units) within the past 2 years or a history of drug abuse within the past 5 years;
- Individuals infected with human immunodeficiency virus (HIV), those in the active stage of hepatitis C virus (HCV) infection (positive for anti-HCV), or those in the active stage of hepatitis B virus (HBV) infection...
- Female people who plan to become pregnant or breastfeed during the study period;
- Those who are sensitive to light or use photosensitive drugs;
- People who are allergic to Hirudoid, tofacitinib, doxycycline, hydroxychloroquine or their ingredients.
The study team makes the final eligibility decision.
Where it's taking place
- Yiwu, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Yiwu, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.